NZ719185A - Crystalline forms of therapeutic compounds and uses thereof - Google Patents
Crystalline forms of therapeutic compounds and uses thereofInfo
- Publication number
- NZ719185A NZ719185A NZ719185A NZ71918514A NZ719185A NZ 719185 A NZ719185 A NZ 719185A NZ 719185 A NZ719185 A NZ 719185A NZ 71918514 A NZ71918514 A NZ 71918514A NZ 719185 A NZ719185 A NZ 719185A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crystalline forms
- pharmaceutical compositions
- particles
- therapeutic compounds
- yloxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- BONKZDDXVSVZED-UHFFFAOYSA-N 7-[3-[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinazolin-7-yl]oxypropyl]-2-oxa-7-azaspiro[3.5]nonane Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN(CC1)CCC21COC2 BONKZDDXVSVZED-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003097 mucus Anatomy 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898741P | 2013-11-01 | 2013-11-01 | |
| US201462039177P | 2014-08-19 | 2014-08-19 | |
| US201462039192P | 2014-08-19 | 2014-08-19 | |
| PCT/US2014/063444 WO2015066482A1 (en) | 2013-11-01 | 2014-10-31 | Crystalline forms of therapeutic compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ719185A true NZ719185A (en) | 2017-11-24 |
Family
ID=53005200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ719185A NZ719185A (en) | 2013-11-01 | 2014-10-31 | Crystalline forms of therapeutic compounds and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US9458169B2 (2) |
| EP (1) | EP3062618B1 (2) |
| JP (2) | JP6426194B2 (2) |
| KR (1) | KR20160099084A (2) |
| CN (2) | CN108530458A (2) |
| AU (1) | AU2014342042B2 (2) |
| CA (1) | CA2928658A1 (2) |
| MX (1) | MX355330B (2) |
| NZ (1) | NZ719185A (2) |
| WO (1) | WO2015066482A1 (2) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9827191B2 (en) * | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US10864219B2 (en) * | 2012-05-03 | 2020-12-15 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US11596599B2 (en) * | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| NZ719185A (en) * | 2013-11-01 | 2017-11-24 | Kala Pharmaceuticals Inc | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324713B2 (en) * | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| KR20190051010A (ko) | 2016-09-08 | 2019-05-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정형 및 그의 용도 |
| EP3697775A1 (en) * | 2017-10-20 | 2020-08-26 | Kala Pharmaceuticals, Inc. | Ret9 and vegfr2 inhibitors |
| CA3084821A1 (en) * | 2017-12-15 | 2019-06-20 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer using exosomes-associated gene editing |
| EP3775258A4 (en) | 2018-03-28 | 2022-01-26 | Board of Regents, The University of Texas System | IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| DK4069252T3 (da) * | 2019-12-02 | 2026-01-12 | Academia Sinica | Pdia4-hæmmere og anvendelse deraf til hæmning af ss-cellepatogenese og behandling af diabetes |
| US20230057383A1 (en) * | 2020-03-21 | 2023-02-23 | Mihan JAFARI JAVID | Composition and methods for prevention and treatment of vascular disorders, neurodegenerative disease and neuropathic disorders |
| KR102491010B1 (ko) * | 2021-09-07 | 2023-01-20 | 경희대학교 산학협력단 | 현탁액에서의 물리적 분쇄를 이용한 안정상 결정 제조방법 |
| CN115820545A (zh) * | 2022-12-28 | 2023-03-21 | 中国农业大学 | 提高卵母细胞体外成熟率的培养基及其应用 |
| CN120603631A (zh) | 2023-01-18 | 2025-09-05 | 纳米形态芬兰有限公司 | 活性药物成分的结晶的方法 |
| CN119097710B (zh) * | 2024-09-11 | 2025-09-02 | 山东大学齐鲁医院 | Ape1抑制剂在制备治疗过敏性鼻炎药物中的应用 |
Family Cites Families (337)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4789724A (en) | 1986-10-17 | 1988-12-06 | Massachusetts Institute Of Technology | Preparation of anhydride copolymers |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| CA1325382C (en) | 1988-01-27 | 1993-12-21 | Takahiro Ogawa | Locally administrable therapeutic composition for inflammatory disease |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5442039A (en) | 1989-07-17 | 1995-08-15 | The Dow Chemical Company | Mesogenic polycyanates and thermosets thereof |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5190956A (en) | 1990-09-07 | 1993-03-02 | Schering Corporation | Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| CZ281628B6 (cs) | 1991-07-29 | 1996-11-13 | Warner-Lambert Company | Deriváty chinazolinu a farmaceutické přípravky na jejich bázi |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6197346B1 (en) | 1992-04-24 | 2001-03-06 | Brown Universtiy Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| US5364884A (en) | 1993-01-21 | 1994-11-15 | Baylor College Of Medicine | Arginine compounds as ocular hypotensive agents |
| US5534259A (en) | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
| EP0712421A1 (en) | 1993-07-23 | 1996-05-22 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| DE69505949T2 (de) | 1994-02-17 | 1999-06-02 | Pankaj Hamilton Ontario Modi | Arzneimittel, impfstoffe und hormone in polylaktidbeschichteten mikropartikel |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| GB9406094D0 (en) | 1994-03-28 | 1994-05-18 | Univ Nottingham And University | Polymer microspheres and a method of production thereof |
| US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| WO1997020578A1 (en) | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
| US6046208A (en) | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| US6106819A (en) | 1996-12-31 | 2000-08-22 | Sucher; David F. | Methods of treating headache and functional extraocular and intraocular myotendinitis |
| US6517860B1 (en) | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
| AU744089C (en) | 1997-01-06 | 2003-07-31 | Cerus Corporation | Frangible compounds for pathogen inactivation |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| GB9713980D0 (en) | 1997-07-03 | 1997-09-10 | Danbiosyst Uk | New conjugates |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| FR2772763B1 (fr) | 1997-12-24 | 2004-01-23 | Sod Conseils Rech Applic | Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| US6165509A (en) | 1998-09-01 | 2000-12-26 | University Of Washington | Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto |
| BR9914167B1 (pt) | 1998-09-29 | 2011-03-09 | compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas. | |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| KR100860295B1 (ko) | 1998-10-08 | 2008-09-25 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| US6372246B1 (en) | 1998-12-16 | 2002-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals |
| CA2358463A1 (en) | 1999-01-08 | 2000-07-13 | Virginia Commonwealth University | Polymeric delivery agents and delivery agent compounds |
| GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| SK288365B6 (sk) * | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| TR200102505T2 (tr) | 1999-02-27 | 2003-01-21 | Boehringer Ingelheim Pharma Kg | 4-amino-kinazolin ve kinolin türevleri. |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| GB9910580D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| GB9910579D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| AR035851A1 (es) | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| US6537993B2 (en) | 2000-03-30 | 2003-03-25 | Penn State Research Foundation | Compounds for enhancing chemotherapy |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| WO2002012226A1 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
| DE10042059A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CZ304344B6 (cs) | 2000-09-11 | 2014-03-19 | Novartis Vaccines & Diagnostics, Inc. | Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu |
| FR2814167B1 (fr) | 2000-09-15 | 2002-11-08 | Aventis Pharma Sa | Preparation de la camptothecine et de ses derives |
| EP1332134A2 (en) | 2000-10-25 | 2003-08-06 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| ES2382636T3 (es) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Método para producir composiciones para la administración mejorada de moléculas bioactivas |
| GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
| GB2370839A (en) | 2001-01-06 | 2002-07-10 | Benedikt Timmerman | Immunogenic complex useful for disease control |
| US6855720B2 (en) | 2001-03-01 | 2005-02-15 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| US20030125344A1 (en) | 2001-03-23 | 2003-07-03 | Bayer Corporation | Rho-kinase inhibitors |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| DE10128110A1 (de) | 2001-06-11 | 2003-01-02 | Univ Hannover | Verbindungen zum Anlagern an Nucleinsäuren |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| EP1408971A4 (en) | 2001-06-21 | 2006-01-25 | Ariad Pharma Inc | NEW QUINOLINES AND THEIR USES |
| WO2003000188A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
| JP4758607B2 (ja) | 2001-06-22 | 2011-08-31 | ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン | 生分解性ポリマー組成物、及びその使用方法 |
| US20050191359A1 (en) | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
| CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| AU2002352868A1 (en) | 2001-11-27 | 2003-06-10 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| WO2003048152A2 (en) | 2001-12-05 | 2003-06-12 | Tularik Inc. | Inflammation modulators |
| EP1454898A4 (en) | 2001-12-13 | 2006-12-13 | Ajinomoto Kk | NEW PHENYL ALANIDE DERIVATIVES |
| WO2003051906A2 (en) | 2001-12-14 | 2003-06-26 | Smithkline Beecham Corporation | Compounds and methods |
| JP4608215B2 (ja) | 2002-02-01 | 2011-01-12 | アストラゼネカ アクチボラグ | キナゾリン化合物 |
| US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| AU2006220411B2 (en) | 2002-03-20 | 2008-06-26 | Alkermes, Inc. | Inhalable Sustained Therapeutic Formulations |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| EP1510221A4 (en) | 2002-06-03 | 2009-04-29 | Mitsubishi Tanabe Pharma Corp | MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| EP1543840A4 (en) | 2002-09-26 | 2006-03-01 | Astellas Pharma Inc | AGENTS FOR IMPROVING THE ABSORPTION OF PHARMACEUTICAL PRODUCTS |
| WO2004044046A2 (en) | 2002-11-08 | 2004-05-27 | Encysive Pharmaceuticals | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| WO2004046101A2 (en) | 2002-11-20 | 2004-06-03 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
| JP2006512387A (ja) | 2002-12-24 | 2006-04-13 | アストラゼネカ アクチボラグ | 化合物 |
| ES2290529T3 (es) | 2002-12-24 | 2008-02-16 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina y su uso farmaceutico. |
| MXPA05006920A (es) | 2002-12-24 | 2006-02-10 | Astrazeneca Ab | Compuestos de quinazolina. |
| US20060167026A1 (en) | 2003-01-06 | 2006-07-27 | Hiroyuki Nawa | Antipsychotic molecular-targeting epithelial growth factor receptor |
| US20050266090A1 (en) | 2003-04-29 | 2005-12-01 | Ales Prokop | Nanoparticular targeting and therapy |
| WO2005044224A2 (en) | 2003-05-02 | 2005-05-19 | Case Western Reserve University | Drug delivery system based on polymer nanoshells |
| CA2523035C (en) | 2003-05-22 | 2011-04-26 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
| US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US20050009809A1 (en) | 2003-07-11 | 2005-01-13 | Matthias Gerlach | Acridine derivatives and their use as medicaments |
| DE10331500A1 (de) | 2003-07-11 | 2005-02-24 | Zentaris Gmbh | Neue Acridin-Derivate und deren Verwendung als Arzneimittel |
| WO2005030131A2 (en) | 2003-09-23 | 2005-04-07 | Replidyne, Inc | Bis-quinazoline compounds for the treatment of bacterial infections |
| WO2005035521A1 (en) | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Substituted quinolines as mcr modulators |
| CN102225926A (zh) | 2003-11-07 | 2011-10-26 | 诺华疫苗和诊断公司 | 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐 |
| GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005073224A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
| JP4932495B2 (ja) | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
| EP1713514B1 (en) | 2004-01-28 | 2021-11-24 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| SE0400284D0 (sv) | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
| US7875624B2 (en) | 2004-02-20 | 2011-01-25 | Novartis Vaccines And Diagnostics, Inc. | Modulating and measuring cellular adhesion |
| TW200529846A (en) | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
| JP2007526322A (ja) | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
| ATE441419T1 (de) | 2004-03-25 | 2009-09-15 | Bausch & Lomb | Verwendung von loteprednoletabonat zur behanldung von trockenen augen |
| WO2005097134A2 (en) | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Quinazoline based protein kinase inhibitors |
| JP4926943B2 (ja) | 2004-04-13 | 2012-05-09 | シンタ ファーマシューティカルズ コーポレーション | Ｉｌ−１２産生を阻害する二塩 |
| US8241670B2 (en) | 2004-04-15 | 2012-08-14 | Chiasma Inc. | Compositions capable of facilitating penetration across a biological barrier |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| AU2005237254B2 (en) | 2004-05-03 | 2010-02-04 | Novartis Ag | Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor |
| US20100226931A1 (en) | 2004-06-24 | 2010-09-09 | Nicholas Valiante | Compounds for immunopotentiation |
| JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
| CN101031551A (zh) | 2004-07-06 | 2007-09-05 | 安吉永生物制药公司 | 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂 |
| EP2364699A1 (en) | 2004-09-13 | 2011-09-14 | Eisai R&D Management Co., Ltd. | Joint use of sulfonamide based compound with angiogenesis inhibitor |
| CA2580659C (en) | 2004-09-15 | 2013-02-26 | Ivx Animal Health, Inc. | Corticosteroid having low systemic absorption |
| WO2006035203A1 (en) * | 2004-09-27 | 2006-04-06 | Astrazeneca Ab | Cancer combination therapy comprising azd2171 and imatinib |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| EP2452670A1 (en) | 2004-10-01 | 2012-05-16 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| TW200616612A (en) | 2004-10-08 | 2006-06-01 | Wyeth Corp | Method for the teatment of polycystic kidney disease field of invention |
| JP2008515961A (ja) * | 2004-10-12 | 2008-05-15 | アストラゼネカ アクチボラグ | 癌に対する使用のためのキナゾリン誘導体 |
| WO2006044660A2 (en) | 2004-10-14 | 2006-04-27 | Vanderbilt University | Functionalized solid lipid nanoparticles and methods of making and using same |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| EP1856179B1 (en) | 2004-12-10 | 2013-05-15 | Kala Pharmaceuticals, Inc. | Functionalized poly (ether-anhydride) block copolymers |
| MX2007010037A (es) | 2005-02-18 | 2008-02-15 | Novartis Vaccines & Diagnostic | Agentes antiangiogenicos con aldesleucina. |
| WO2006092430A1 (de) | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
| DE102005009705A1 (de) | 2005-03-03 | 2006-09-07 | Universität des Saarlandes | Selektive Hemmstoffe humaner Corticoidsynthasen |
| DE102005011786A1 (de) | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
| US8048889B2 (en) | 2005-03-29 | 2011-11-01 | Xtl Biopharmaceuticals Ltd. | 3,4-disubstituted coumarin and quinolone compounds |
| CA2603345C (en) | 2005-04-01 | 2017-05-02 | Insa Rouen | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| CA2607608A1 (en) | 2005-05-10 | 2006-11-16 | Alcon, Inc. | Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders |
| BRPI0609928A2 (pt) | 2005-05-18 | 2010-05-11 | Wyeth Corp | inibidores de quinase tpl-2 de 3-cianoquinolina e métodos de fabricação e uso dos mesmos |
| BRPI0610147A2 (pt) | 2005-05-25 | 2010-06-01 | Wyeth Corp | método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas |
| CA2608394A1 (en) | 2005-05-25 | 2006-11-30 | Wyeth | Methods of preparing 3-cyano-quinolines and intermediates made thereby |
| CN1313449C (zh) | 2005-07-14 | 2007-05-02 | 沈阳中海生物技术开发有限公司 | 新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途 |
| EP1925941B1 (en) | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| FR2889527A1 (fr) | 2005-08-05 | 2007-02-09 | Servier Lab | Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP4792262B2 (ja) | 2005-09-09 | 2011-10-12 | 富士フイルム株式会社 | 有機電界発光素子及び錯体化合物 |
| US7732613B2 (en) | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| AU2006293410B2 (en) | 2005-09-20 | 2012-10-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Nanoparticles for targeted delivery of active agents |
| US7875602B2 (en) | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
| CN1955183B (zh) | 2005-10-28 | 2011-04-20 | 中国医学科学院药物研究所 | 20-位酯化的喜树碱衍生物、其制法和其药物组合物与用途 |
| US20070149523A1 (en) | 2005-11-14 | 2007-06-28 | Jan Ehlert | Thiazole Analogues and Uses Thereof |
| EP1785420A1 (en) | 2005-11-14 | 2007-05-16 | 4Sc Ag | Thiazole analogues and uses thereof |
| WO2007068615A2 (en) | 2005-12-14 | 2007-06-21 | F. Hoffmann-La Roche Ag | Hcv prodrug formulation |
| US20070149480A1 (en) | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| WO2007081978A2 (en) | 2006-01-11 | 2007-07-19 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor / c-met activity |
| US20070196860A1 (en) | 2006-01-18 | 2007-08-23 | Invitrogen Corporation | Methods for Measuring Real Time Kinase Activity |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| WO2007100711A2 (en) | 2006-02-24 | 2007-09-07 | Investigen, Inc. | Methods and compositions for detecting polynucleotides |
| GB2444101A (en) | 2006-02-24 | 2008-05-28 | Investigen Inc | Methods and compositions for detecting polynucleotides |
| WO2007104696A1 (en) | 2006-03-15 | 2007-09-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antimalarial agents having polyaromatic structure |
| GB0605691D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| KR101394768B1 (ko) | 2006-03-30 | 2014-05-21 | 드라이스 파마슈티컬스 아이엔씨 | 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물 |
| SI2010496T1 (sl) | 2006-04-14 | 2010-11-30 | Astrazeneca Ab | anilinokinolin karboksamidi kot inhibitorji CSF R kinaze |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| JP2009537518A (ja) | 2006-05-15 | 2009-10-29 | エックスティーエル バイオファーマシューティカルズ，リミテッド | ３，４−二置換クマリン及びキノロン化合物 |
| WO2007133808A2 (en) | 2006-05-15 | 2007-11-22 | Liquidia Technologies, Inc. | Nano-particles for cosmetic applications |
| US7691811B2 (en) | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| JP2009539878A (ja) | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| EP2044939A1 (en) | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| EP2037924A2 (en) | 2006-07-07 | 2009-03-25 | Steven P. Govek | Bicyclic heteroaryl inhibitors of pde4 |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| DE602007012559D1 (de) | 2006-09-08 | 2011-03-31 | Univ Johns Hopkins | H die schleimhaut |
| AU2007296745B2 (en) | 2006-09-11 | 2011-12-01 | Curis, Inc. | Quinazoline based EGFR inhibitors |
| US8821943B2 (en) | 2006-09-12 | 2014-09-02 | Board Of Regents Of The University Of Nebraska | Methods and compositions for targeted delivery of therapeutic agents |
| US20080096193A1 (en) | 2006-10-24 | 2008-04-24 | Charles Robert Bupp | Methods and compositions for detecting polynucleotides |
| CL2007003158A1 (es) | 2006-11-02 | 2008-05-16 | Astrazeneca Ab | Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion. |
| TW200829555A (en) | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| ES2392156T3 (es) | 2006-12-20 | 2012-12-05 | Amgen Inc. | Heterociclos sustituidos y métodos de uso |
| CN100540551C (zh) | 2007-02-01 | 2009-09-16 | 中国药科大学 | 喹啉衍生物、其制备方法及其医药用途 |
| CN100540552C (zh) | 2007-02-01 | 2009-09-16 | 中国药科大学 | 3-氰基喹啉衍生物、其制备方法及其医药用途 |
| WO2008097976A1 (en) | 2007-02-09 | 2008-08-14 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| JP2008214323A (ja) | 2007-03-08 | 2008-09-18 | Kyowa Hakko Kogyo Co Ltd | 皮膚疾患の治療及び／または予防剤 |
| CN101679308B (zh) | 2007-03-14 | 2014-05-07 | 埃克塞里艾克西斯公司 | Hedgehog途径抑制剂 |
| WO2008113161A1 (en) | 2007-03-19 | 2008-09-25 | Ulysses Pharmaceutical Products Inc. | Phosphate prodrugs of quinazolinyl nitrofurans, methods of obtaining, and use of same |
| DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
| DE102007017654A1 (de) | 2007-04-12 | 2008-10-16 | Henkel Ag & Co. Kgaa | Bis(hydroxychinolin)-Metallkomplexe als Bleichkatalysatoren |
| CN101317847B (zh) | 2007-06-06 | 2010-10-13 | 深圳市瑞谷医药技术有限公司 | 一种眼用或耳鼻用药物组合物及其用途 |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| AR067027A1 (es) | 2007-06-19 | 2009-09-30 | Astrazeneca Ab | Derivados de 2, 3-dihidro-1h-pirrol[3, 4b]quinolin-1-ona, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion de la actividad del receptor gaba a. |
| WO2009014730A1 (en) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| WO2009018092A1 (en) | 2007-07-27 | 2009-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Supramolecular functionalization of graphitic nanoparticles for drug delivery |
| CN101108846B (zh) | 2007-08-10 | 2011-02-09 | 东南大学 | 4-芳香氨基喹唑啉衍生物及制备方法和在制药中的应用 |
| US20090062337A1 (en) | 2007-08-31 | 2009-03-05 | Wysis Technology Foundation, Inc. | Treatment of Microbial Infections |
| WO2009030224A2 (de) | 2007-09-07 | 2009-03-12 | Schebo Biotech Ag | Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen |
| DE102008012435A1 (de) * | 2008-02-29 | 2009-09-03 | Schebo Biotech Ag | Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie |
| TW200922590A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
| JP2010540459A (ja) | 2007-09-24 | 2010-12-24 | トラガラ ファーマシューティカルズ，インク． | Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法 |
| ES2385118T3 (es) | 2008-01-17 | 2012-07-18 | Bayer Pharma Aktiengesellschaft | Derivados de quinazolina sustituida con sulfoximina como inmunomoduladores, su preparación y uso como medicamentos |
| WO2009094211A1 (en) | 2008-01-22 | 2009-07-30 | Concert Pharmaceuticals Inc. | Quinazoline compounds and methods of treating cancer |
| US8133695B2 (en) | 2008-02-28 | 2012-03-13 | Life Technologies Corporation | Fluorescence polarization hERG assay |
| TW201000107A (en) | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
| EP2288383A1 (en) | 2008-05-14 | 2011-03-02 | Amgen, Inc | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| EP2149565A1 (de) | 2008-07-24 | 2010-02-03 | Bayer Schering Pharma AG | Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen |
| US8211911B2 (en) | 2008-08-19 | 2012-07-03 | Guoqing Paul Chen | Compounds as kinase inhibitors |
| TWI580441B (zh) | 2008-09-19 | 2017-05-01 | 愛爾康研究有限公司 | 穩定的藥學次微米懸浮液及其形成方法 |
| EP2340244A4 (en) * | 2008-10-14 | 2012-07-25 | Ning Xi | COMPOUNDS AND APPLICATION PROCEDURES |
| WO2010056758A1 (en) | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
| CN101747306B (zh) | 2008-11-28 | 2012-08-29 | 中国中化股份有限公司 | 取代醚类化合物及其应用 |
| JP5471063B2 (ja) | 2009-02-23 | 2014-04-16 | 住友化学株式会社 | 環状化合物、その金属錯体及び変性金属錯体 |
| TWI461197B (zh) | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
| US20120022057A1 (en) | 2009-03-18 | 2012-01-26 | Schering Corporation | Bicyclic compounds as inhibitors of diacyglycerol acyltransferase |
| US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| US9241928B2 (en) | 2009-06-26 | 2016-01-26 | The General Hospital Corporation | Antimicrobial compounds |
| CN102596200A (zh) | 2009-11-07 | 2012-07-18 | 默克专利有限公司 | 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类 |
| EP2335686A1 (en) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
| DE102010006121B4 (de) | 2010-01-29 | 2022-08-11 | Merck Patent Gmbh | Materialien für organische Elektrolumineszenzvorrichtungen |
| DE102010007938A1 (de) | 2010-02-12 | 2011-10-06 | Merck Patent Gmbh | Elektrolumineszierende Polymere, Verfahren zu ihrer Herstellung sowie ihre Verwendung |
| WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE |
| JP5654246B2 (ja) | 2010-03-03 | 2015-01-14 | 一般社団法人ファルマバレープロジェクト支援機構 | キナゾリン化合物を有効成分とする医薬組成物 |
| TWI516264B (zh) | 2010-05-06 | 2016-01-11 | 臺北醫學大學 | 芳香醯喹啉化合物 |
| JP5921535B2 (ja) | 2010-06-16 | 2016-05-24 | ディナバックス テクノロジーズ コーポレイション | Ｔｌｒ７および／またはｔｌｒ９阻害剤を用いる治療の方法 |
| DE102010023949A1 (de) | 2010-06-16 | 2011-12-22 | F. Holzer Gmbh | In-situ Lecithin-Mikroemulsionsgel-Formulierung |
| CA2803890A1 (en) | 2010-06-25 | 2011-12-29 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
| US20120252756A1 (en) | 2010-06-25 | 2012-10-04 | Coffey Martin J | Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye |
| JP5826261B2 (ja) | 2010-06-28 | 2015-12-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン |
| WO2012012627A1 (en) | 2010-07-22 | 2012-01-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of preventing or treating viral infection |
| WO2012013884A1 (fr) | 2010-07-29 | 2012-02-02 | Laboratoires Fournier Sa | Composes pour le traitement/la prevention des maladies inflammatoires oculaires |
| SG187654A1 (en) | 2010-07-30 | 2013-03-28 | Ranbaxy Lab Ltd | Matrix metalloproteinase inhibitors |
| TW201211007A (en) | 2010-08-27 | 2012-03-16 | Gruenenthal Gmbh | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| WO2012040499A2 (en) | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
| MX2013003362A (es) | 2010-09-24 | 2013-06-05 | Ranbaxy Lab Ltd | Inhibidores de metaloproteinasa de matriz. |
| CA2812319A1 (en) | 2010-09-24 | 2012-03-29 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
| AU2011306397A1 (en) | 2010-09-24 | 2013-05-02 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
| CN103347520A (zh) | 2010-10-13 | 2013-10-09 | 波士顿大学管理委员会 | 用作癌症化学治疗的晚期sv40因子（lsf）的抑制剂 |
| EP2629760A4 (en) | 2010-10-22 | 2014-04-02 | Bind Therapeutics Inc | THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT |
| WO2012061703A1 (en) | 2010-11-05 | 2012-05-10 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
| DE102010050570A1 (de) | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors |
| WO2012064898A1 (en) | 2010-11-09 | 2012-05-18 | Yuan Chen | Singleton inhibitors of sumoylation enzymes and methods for their use |
| CA2818712C (en) | 2010-11-24 | 2020-11-10 | Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services | Compositions and methods for treating or preventing lupus |
| WO2012074980A2 (en) | 2010-12-01 | 2012-06-07 | Dara Biosciences, Inc. | Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives |
| AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
| WO2012088431A1 (en) | 2010-12-23 | 2012-06-28 | Ironwood Pharmaceuticals, Inc. | Faah inhibitors |
| WO2012093117A1 (en) | 2011-01-03 | 2012-07-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases |
| US8980909B2 (en) | 2011-01-12 | 2015-03-17 | Crystal Biopharmaceutical Llc | HDAC inhibiting derivatives of camptothecin |
| WO2012106534A2 (en) | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| EP2678052B1 (en) | 2011-02-24 | 2018-09-26 | Emory University | Jab1 blocking compositions for ossification and methods related thereto |
| WO2012127506A1 (en) | 2011-03-22 | 2012-09-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| US10316371B2 (en) | 2011-03-29 | 2019-06-11 | Trana Discovery, Inc. | Screening methods for identifying specific Staphylococcus aureus inhibitors |
| AU2012242807A1 (en) | 2011-04-14 | 2013-11-07 | Allergan, Inc. | Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| US8507686B2 (en) | 2011-04-14 | 2013-08-13 | Allergan, Inc. | Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators |
| SG194209A1 (en) | 2011-04-18 | 2013-11-29 | Allergan Inc | Substituted bicyclic methyl amine derivatives as sphingosine-1-phosphate receptors modulators |
| AU2012249601A1 (en) | 2011-04-26 | 2013-05-09 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| US8835410B2 (en) | 2011-05-10 | 2014-09-16 | Bodor Laboratories, Inc. | Treatment of eyelid dermatitis |
| KR101967938B1 (ko) | 2011-05-12 | 2019-04-10 | 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 | 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물 |
| EP2710119A4 (en) | 2011-05-17 | 2015-02-18 | Cleave Biosciences Inc | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION |
| WO2012162698A1 (en) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of immune disorders |
| KR20140048216A (ko) | 2011-06-29 | 2014-04-23 | 오츠카 세이야쿠 가부시키가이샤 | 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법 |
| WO2013013614A1 (zh) | 2011-07-28 | 2013-01-31 | 南京英派药业有限公司 | 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用 |
| JP5753027B2 (ja) | 2011-08-22 | 2015-07-22 | ユー・ディー・シー アイルランド リミテッド | 有機電界発光素子、化合物、並びに該素子を用いた発光装置、表示装置及び照明装置 |
| TW202023575A (zh) | 2011-09-16 | 2020-07-01 | 美商遠景生物製藥股份有限公司 | 安定之普維酮—碘組成物 |
| WO2013061269A1 (en) | 2011-10-26 | 2013-05-02 | Micro Labs Limited | Combinations of loteprednol and olopatadine for the treatment of ocular allergies |
| TWI549679B (zh) | 2011-11-03 | 2016-09-21 | 台灣微脂體股份有限公司 | 疏水性喜樹鹼衍生物之醫藥組合物 |
| WO2013065029A1 (en) | 2011-11-04 | 2013-05-10 | Micro Labs Limited | Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections |
| US20130116279A1 (en) | 2011-11-07 | 2013-05-09 | Kalypsys, Inc. | Bicyclic heteroaryl inhibitors of pde4 |
| US9458131B2 (en) | 2011-11-08 | 2016-10-04 | Emory University | Compounds and compositions used to epigenetically transform cells and methods related thereto |
| TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
| CN103102342B (zh) | 2011-11-14 | 2014-10-29 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
| CN103102345B (zh) | 2011-11-14 | 2015-06-03 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
| EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| US20140329913A1 (en) | 2011-12-14 | 2014-11-06 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
| CN103183674B (zh) | 2011-12-31 | 2017-09-12 | 江苏先声药业有限公司 | 一类稠杂环衍生物及其应用 |
| WO2013118071A1 (en) | 2012-02-09 | 2013-08-15 | Glenmark Pharmaceuticals S.A. | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| WO2013120057A1 (en) | 2012-02-10 | 2013-08-15 | The Regents Of The University Of California | First row metal-based catalysts for hydosilylation |
| CN103304572A (zh) | 2012-03-09 | 2013-09-18 | 上海医药集团股份有限公司 | 一类3-氰基喹啉类化合物及其药用组合物和应用 |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| NZ742005A (en) | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| KR102310775B1 (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
| AU2013256064B2 (en) | 2012-05-03 | 2018-01-04 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| CA2875348A1 (en) | 2012-06-01 | 2013-12-05 | Oxalys Pharmaceuticals | Chemical suppressors of neurotoxicity in synucleinopathic diseases |
| WO2013188813A2 (en) | 2012-06-15 | 2013-12-19 | The Regents Of The University Of California | Novel therapeutics for brain cancer |
| US9062026B2 (en) | 2012-07-20 | 2015-06-23 | Cleave Biosciences, Inc. | Fused pyrimidines and substituted quinazolines as inhibitors of p97 |
| CN103804292A (zh) | 2012-11-05 | 2014-05-21 | 江苏唐果医药科技有限公司 | Hdm2和hdmx双重抑制剂3－腈基喹啉衍生物及其制备方法与应用 |
| KR20150080619A (ko) | 2012-11-08 | 2015-07-09 | 아지오스 파마슈티컬스 아이엔씨. | 치료적 화합물 및 조성물 |
| US20150259649A1 (en) | 2012-11-08 | 2015-09-17 | Emory University | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto |
| WO2014074926A1 (en) | 2012-11-09 | 2014-05-15 | Rutgers, The State University Of New Jersey | Therapeutic hydroxyquinolones |
| KR102051910B1 (ko) | 2012-11-30 | 2019-12-09 | 에스에프씨주식회사 | 중수소 치환된 유기금속 착물 및 이를 포함하는 유기 발광 소자 |
| CN103848785B (zh) | 2012-12-04 | 2016-07-13 | 上海医药集团股份有限公司 | 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途 |
| KR102146232B1 (ko) | 2012-12-21 | 2020-08-20 | 메르크 파텐트 게엠베하 | 금속 착물 |
| KR102084421B1 (ko) | 2013-02-15 | 2020-03-05 | 에스에프씨주식회사 | 신규한 유기 화합물 및 이를 포함하는 유기 발광 소자 |
| JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
| KR102118013B1 (ko) | 2013-02-22 | 2020-06-05 | 에스에프씨주식회사 | 신규한 유기 화합물 및 이를 포함하는 유기 발광 소자 |
| CA2903082C (en) | 2013-03-04 | 2021-06-22 | Advanced Medical Research Institute Of Canada | Quinoline sulfonyl derivatives and uses thereof |
| WO2014141057A2 (en) | 2013-03-12 | 2014-09-18 | Mahesh Kandula | Compositions and methods for the treatment of cancer |
| WO2014141110A2 (en) | 2013-03-14 | 2014-09-18 | Curadev Pharma Pvt. Ltd. | Aminonitriles as kynurenine pathway inhibitors |
| JP6464139B2 (ja) | 2013-03-14 | 2019-02-06 | コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ | ブロモドメイン含有タンパク質の阻害のための方法および組成物 |
| AU2014233757B2 (en) | 2013-03-18 | 2017-12-21 | Genoscience Pharma | Quinolines derivatives as novel anticancer agents |
| WO2014182954A1 (en) | 2013-05-08 | 2014-11-13 | Colorado Seminary, Which Owns And Operates The University Of Denver | Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase |
| JP2016524607A (ja) | 2013-05-16 | 2016-08-18 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｈｉｖ−１インテグラーゼの薬物耐性株を阻害するための化合物 |
| CN105636944B (zh) | 2013-10-14 | 2019-03-01 | 默克专利有限公司 | 用于电子器件的材料 |
| NZ719185A (en) | 2013-11-01 | 2017-11-24 | Kala Pharmaceuticals Inc | Crystalline forms of therapeutic compounds and uses thereof |
-
2014
- 2014-10-31 NZ NZ719185A patent/NZ719185A/en not_active IP Right Cessation
- 2014-10-31 AU AU2014342042A patent/AU2014342042B2/en not_active Ceased
- 2014-10-31 JP JP2016552255A patent/JP6426194B2/ja not_active Expired - Fee Related
- 2014-10-31 CA CA2928658A patent/CA2928658A1/en not_active Abandoned
- 2014-10-31 CN CN201810252366.6A patent/CN108530458A/zh active Pending
- 2014-10-31 MX MX2016005668A patent/MX355330B/es active IP Right Grant
- 2014-10-31 US US14/530,092 patent/US9458169B2/en not_active Expired - Fee Related
- 2014-10-31 CN CN201480065624.XA patent/CN106061261B/zh not_active Expired - Fee Related
- 2014-10-31 WO PCT/US2014/063444 patent/WO2015066482A1/en not_active Ceased
- 2014-10-31 KR KR1020167014146A patent/KR20160099084A/ko not_active Withdrawn
- 2014-10-31 EP EP14857737.2A patent/EP3062618B1/en active Active
-
2015
- 2015-12-28 US US14/981,105 patent/US9790232B2/en not_active Expired - Fee Related
-
2017
- 2017-09-22 US US15/712,645 patent/US10160765B2/en active Active
-
2018
- 2018-10-24 JP JP2018199914A patent/JP2019038825A/ja active Pending
- 2018-11-08 US US16/184,760 patent/US10618906B2/en active Active
-
2020
- 2020-03-02 US US16/806,819 patent/US10975090B2/en not_active Expired - Fee Related
-
2021
- 2021-03-10 US US17/197,702 patent/US11713323B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9458169B2 (en) | 2016-10-04 |
| EP3062618A1 (en) | 2016-09-07 |
| US11713323B2 (en) | 2023-08-01 |
| CA2928658A1 (en) | 2015-05-07 |
| AU2014342042B2 (en) | 2017-08-17 |
| JP6426194B2 (ja) | 2018-11-21 |
| KR20160099084A (ko) | 2016-08-19 |
| CN106061261A (zh) | 2016-10-26 |
| US20190077810A1 (en) | 2019-03-14 |
| CN106061261B (zh) | 2018-04-24 |
| US20210355133A1 (en) | 2021-11-18 |
| US9790232B2 (en) | 2017-10-17 |
| US10975090B2 (en) | 2021-04-13 |
| US20160115176A1 (en) | 2016-04-28 |
| US20180009824A1 (en) | 2018-01-11 |
| WO2015066482A1 (en) | 2015-05-07 |
| MX2016005668A (es) | 2016-10-28 |
| US20200216459A1 (en) | 2020-07-09 |
| JP2019038825A (ja) | 2019-03-14 |
| CN108530458A (zh) | 2018-09-14 |
| MX355330B (es) | 2018-04-16 |
| EP3062618B1 (en) | 2020-02-05 |
| US10160765B2 (en) | 2018-12-25 |
| AU2014342042A1 (en) | 2016-05-12 |
| EP3062618A4 (en) | 2017-07-12 |
| US10618906B2 (en) | 2020-04-14 |
| US20150125535A1 (en) | 2015-05-07 |
| JP2016535100A (ja) | 2016-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| GEP201706780B (en) | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| MX360598B (es) | Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos. | |
| TN2016000238A1 (en) | Tricyclic compounds as anticancer agents. | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| UA115558C2 (uk) | Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань | |
| IN2015DN01156A (2) | ||
| MX363457B (es) | Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1). | |
| NZ700928A (en) | Dna-pk inhibitors | |
| MX2015009037A (es) | Enjuague nasal con miel. | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MX2015010128A (es) | Derivados de piridazinona macrociclicos. | |
| CA2818187C (en) | Bromodomain inhibitors and uses thereof | |
| WO2014152029A3 (en) | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors | |
| MX370017B (es) | Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a. | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
| IN2012DN00239A (2) | ||
| MX357888B (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
| MX2015000179A (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| HK1228278A1 (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| UA104730C2 (en) | Isoquinolinone derivatives as nk3 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2019 BY DENNEMEYER + CO Effective date: 20180927 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2020 BY DENNEMEYER + CO. Effective date: 20190923 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2021 BY DENNEMEYER + CO. Effective date: 20201019 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2022 BY DENNEMEYER + CO. Effective date: 20211018 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2023 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20221024 |
|
| LAPS | Patent lapsed |